Literature DB >> 30181365

Assessment of the In Vivo Efficacy of WCK 5222 (Cefepime-Zidebactam) against Carbapenem-Resistant Acinetobacter baumannii in the Neutropenic Murine Lung Infection Model.

Lindsay M Avery1, Kamilia Abdelraouf1, David P Nicolau2,3.   

Abstract

We evaluated the in vivo efficacy of human-simulated WCK 5222 (cefepime-zidebactam) against cefepime-resistant Acinetobacter baumannii strains (n = 13) in the neutropenic murine lung infection model. Twelve isolates were meropenem resistant. In control animals and those that received cefepime or zidebactam alone, the mean bacterial growth at 24 h was >2 log10 CFU/lung compared with 0-h controls (6.32 ± 0.33 log10 CFU/lung). WCK 5222 produced a decline in the bacterial burden for all isolates (mean reduction, -3.34 ± 0.85 log10 CFU/lung) and demonstrated remarkable potency.
Copyright © 2018 American Society for Microbiology.

Entities:  

Keywords:  Acinetobacter; carbapenem resistant; lung infection

Mesh：

Substances：

Year:  2018        PMID： 30181365      PMCID： PMC6201064          DOI： 10.1128/AAC.00948-18

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  14 in total

1.  Pharmacokinetics and pulmonary disposition of tedizolid and linezolid in a murine pneumonia model under variable conditions.

Authors:  Rebecca A Keel; Jared L Crandon; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2012-03-19       Impact factor: 5.191

2.  In vitro activity of cefepime/zidebactam (WCK 5222) against Gram-negative bacteria.

Authors:  David M Livermore; Shazad Mushtaq; Marina Warner; Anna Vickers; Neil Woodford
Journal:  J Antimicrob Chemother       Date:  2017-05-01       Impact factor: 5.790

3.  In Vitro-In Vivo Discordance with Humanized Piperacillin-Tazobactam Exposures against Piperacillin-Tazobactam-Resistant/Pan-β-Lactam-Susceptible Escherichia coli.

Authors:  M L Monogue; D P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2016-11-21       Impact factor: 5.191

Review 4.  Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men.

Authors:  W A Craig
Journal:  Clin Infect Dis       Date:  1998-01       Impact factor: 9.079

5.  In Vitro-In Vivo Discordance with Humanized Piperacillin-Tazobactam Exposures against Piperacillin-Tazobactam-Resistant/Pan-β-Lactam-Susceptible Klebsiella pneumoniae Strains.

Authors:  S M Stainton; M L Monogue; D P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2017-06-27       Impact factor: 5.191

6.  Risk factors and mortality of patients with nosocomial carbapenem-resistant Acinetobacter baumannii pneumonia.

Authors:  Yu-long Zheng; Yu-feng Wan; Li-yang Zhou; Mao-lin Ye; Shu Liu; Chuan-qin Xu; Yuan-qiang He; Jian-hui Chen
Journal:  Am J Infect Control       Date:  2013-03-21       Impact factor: 2.918

Review 7.  Plazomicin: an investigational therapy for the treatment of urinary tract infections.

Authors:  Ilias Karaiskos; Maria Souli; Helen Giamarellou
Journal:  Expert Opin Investig Drugs       Date:  2015-09-30       Impact factor: 6.206

8.  Efficacies of ceftazidime-avibactam and ceftazidime against Pseudomonas aeruginosa in a murine lung infection model.

Authors:  Seth T Housman; Jared L Crandon; Wright W Nichols; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2013-12-16       Impact factor: 5.191

Review 9.  Anticipating the Unpredictable: A Review of Antimicrobial Stewardship and Acinetobacter Infections.

Authors:  Eric Wenzler; Debra A Goff; Romney Humphries; Ellie J C Goldstein
Journal:  Infect Dis Ther       Date:  2017-03-04

Review 10.  Biology of Acinetobacter baumannii: Pathogenesis, Antibiotic Resistance Mechanisms, and Prospective Treatment Options.

Authors:  Chang-Ro Lee; Jung Hun Lee; Moonhee Park; Kwang Seung Park; Il Kwon Bae; Young Bae Kim; Chang-Jun Cha; Byeong Chul Jeong; Sang Hee Lee
Journal:  Front Cell Infect Microbiol       Date:  2017-03-13       Impact factor: 5.293
View more
  14 in total

1.  In Vivo Efficacy of WCK 5222 (Cefepime-Zidebactam) against Multidrug-Resistant Pseudomonas aeruginosa in the Neutropenic Murine Thigh Infection Model.

Authors:  Marguerite L Monogue; Jennifer Tabor-Rennie; Kamilia Abdelraouf; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2019-06-24       Impact factor: 5.191

2.  The Novel β-Lactam Enhancer Zidebactam Augments the In Vivo Pharmacodynamic Activity of Cefepime in a Neutropenic Mouse Lung Acinetobacter baumannii Infection Model.

Authors:  S S Bhagwat; H Periasamy; S S Takalkar; S R Palwe; H N Khande; M V Patel
Journal:  Antimicrob Agents Chemother       Date:  2019-03-27       Impact factor: 5.191

3.  Human-Simulated Antimicrobial Regimens in Animal Models: Transparency and Validation Are Imperative.

Authors:  Christian M Gill; Tomefa E Asempa; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2020-07-22       Impact factor: 5.191

Review 4.  Is it time to move away from polymyxins?: evidence and alternatives.

Authors:  Rajeev Soman; Yamuna Devi Bakthavatchalam; Abinaya Nadarajan; Hariharan Triplicane Dwarakanathan; Ramasubramanian Venkatasubramanian; Balaji Veeraraghavan
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2020-10-02       Impact factor: 3.267

5.  WCK 5222 (Cefepime/Zidebactam) Pharmacodynamic Target Analysis against Metallo-β-lactamase producing Enterobacteriaceae in the Neutropenic Mouse Pneumonia Model.

Authors:  Alexander J Lepak; Miao Zhao; David R Andes
Journal:  Antimicrob Agents Chemother       Date:  2019-10-07       Impact factor: 5.191

6.  In Vitro and In Vivo Activities of β-Lactams in Combination with the Novel β-Lactam Enhancers Zidebactam and WCK 5153 against Multidrug-Resistant Metallo-β-Lactamase-Producing Klebsiella pneumoniae.

Authors:  Bartolome Moya; Isabel M Barcelo; Gabriel Cabot; Gabriel Torrens; Snehal Palwe; Prashant Joshi; Kushal Umarkar; Swapna Takalkar; Hariharan Periasamy; Sachin Bhagwat; Mahesh Patel; German Bou; Antonio Oliver
Journal:  Antimicrob Agents Chemother       Date:  2019-04-25       Impact factor: 5.191

Review 7.  New Drugs for the Treatment of Pseudomonas aeruginosa Infections with Limited Treatment Options: A Narrative Review.

Authors:  Angela Raffaella Losito; Francesca Raffaelli; Paola Del Giacomo; Mario Tumbarello
Journal:  Antibiotics (Basel)       Date:  2022-04-26

Review 8.  The latest advances in β-lactam/β-lactamase inhibitor combinations for the treatment of Gram-negative bacterial infections.

Authors:  Krisztina M Papp-Wallace
Journal:  Expert Opin Pharmacother       Date:  2019-09-09       Impact factor: 3.889

9.  In Vivo Efficacy of Humanized WCK 5222 (Cefepime-Zidebactam) Exposures against Carbapenem-Resistant Acinetobacter baumannii in the Neutropenic Thigh Model.

Authors:  Safa S Almarzoky Abuhussain; Lindsay M Avery; Kamilia Abdelraouf; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2018-12-21       Impact factor: 5.191

10.  In vivo efficacy of WCK 6777 (ertapenem/zidebactam) against carbapenemase-producing Klebsiella pneumoniae in the neutropenic murine pneumonia model.

Authors:  Matthew Gethers; Iris Chen; Kamilia Abdelraouf; David P Nicolau
Journal:  J Antimicrob Chemother       Date:  2022-06-29       Impact factor: 5.758
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.